Influence of tiapride on platelet counts in healthy volunteers and patients with movement disorders.

Abstract

BACKGROUND:

The selective D2 antagonist tiapride is administered in various movement disorders. Furthermore, there are indications that tiapride increases platelet counts.

AIM:

To characterize tiapride's potential to increase platelet counts in healthy subjects and patients with movement disorders.

METHODS:

In Part A, 10 healthy volunteers received tiapride (300 mg/day) for 21 days in a longitudinal, prospective, open trial. One hundred healthy subjects served as controls. Part B was a retrospective analysis of 15 patients with movement disorders on tiapride [Huntington's disease (n=6), Morbus Little (n=3), hyperkinetic syndromes of undetermined etiology (n=3), blepharospasm (n=1), cervical dystonia (n=1), perioral dyskinesia (n=1)] and 15 age- and sex-matched controls.

RESULTS:

Part A: Although serum prolactin levels increased by 526+/-14%, confirming good drug compliance, tiapride elicited only minor changes in platelet counts. Part B: Platelet counts correlated positively with the dose of tiapride (100-800 mg/day; r=.67; P=.007). Platelet counts were significantly higher in patients on tiapride compared to healthy age-matched controls (P<.001). Four patients responded to an increase in the tiapride dosage with an increase in platelet count by 97-173 cells/nl.

CONCLUSION:

Three weeks of treatment with tiapride (300 mg/day) is insufficient to elevate platelet counts to a clinically relevant extent in young healthy volunteers. However, in elderly patients with movement disorders tiapride treatment is associated with markedly increased platelet counts.

• Authors: Nicole Kotzailias, Josef Finsterer, Susanne Aull, Hans-Georg Eichler, Barbara Pratscher, Bernd Jilma
• Journal: Progress in neuro-psychopharmacology & biological psychiatry (Prog Neuropsychopharmacol Biol Psychiatry) Vol. 27 Issue 4 Pg. 595-9 (Jun 2003) ISSN: 0278-5846 [Print] England
• PMID: 12787844 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Dyskinesia Agents
• Tiapamil Hydrochloride

Topics

• Administration, Oral
• Adult
• Age Factors
• Anti-Dyskinesia Agents (pharmacology)
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Movement Disorders (drug therapy)
• Platelet Count
• Thrombocytopenia (drug therapy)
• Tiapamil Hydrochloride (pharmacology)